alexa Surface Derivatization Of Zirconium Phosphate Nanoplatelets: Potential Nanocarrier Of Doxorubicin Anticancer Drug | 65550
ISSN: 2150-3494

Chemical Sciences Journal
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th European Chemistry Congress

Julissa Gonzalez Villegas
University of Puerto, United States
Posters & Accepted Abstracts: Chem Sci J
DOI: 10.4172/2150-3494-C1-009
Abstract
Surface modification of doxorubicin anticancer drug (DOX) intercalated zirconium phosphate (ZrP) nanoparticles ([email protected]) is proposed to improve the potential of this drug delivery system for cancer therapy. The surface of [email protected] nanoparticles was modified with an amorphous layer of Zr(IV) followed by modification with monomethyl-polyethylene glycol-monophosphate (m-PEG-PO3) to increase the [email protected] biocompatibility. 31P{1H}MAS NMR data shows a new peak at -26 ppm corresponding to the PO4 3- groups coordinated with Zr(IV) on the surface. m-PEG-PO3/Zr(IV)/[email protected] spectra shows no additional resonance centered at δ of -22.6 ppm generated by proton-phosphorous cross polarization indicating no partial PEG intercalation in the interlaminar space. Simulated body fluid (SBF) was used to determine the in vitro release of DOX from [email protected], Zr(IV)/[email protected] ZrP, and m-PEG-PO3/ Zr(IV)/[email protected] MTS cell viability assay reveal that m-PEG-PO3/ Zr(IV)/[email protected] exhibited a 20% increase in the toxicity comparing with free DOX when PC3 cells are exposed for 48 h. m-PEG-PO3 polymer coating of [email protected] nanoparticles promise to have a strong impact on the targeting, distribution and degradation of the nanoparticles under physiological environment that should result in a more efficient chemotherapy agent than free doxorubicin.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

bus[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version